RWD Differences Across 6 European HTAs

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)’s Value in Health recently published a new study revealing notable differences in how European health technology assessment (HTA) agencies assess real-world data. Find out more here. (Source: ISPOR)

You might also be interested in:

Toward A More Precise Public Health Strategy in the Battle… 08/13/2020
Key Innovations Coming From The Next Generation of PBM’s 08/12/2020
New Roadmap Aims to Transform Healthcare Landscape by… 08/13/2020
Gaps in Health Data are Barrier to Health Equity 01/14/2021
[Webinar] How can VA/HTA Inform Policy Interventions and… 10/15/2020
Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
Invoke a 1980's Law to Lower Cost of Remdesivir for COVID-19,… 08/07/2020